Notable novel druggable genes include FKBP5 and CDC42BPA. Functional studies have suggested that FKBP5 expression in subcutaneous adipose tissue may induce insulin resistance (Pereira et al., 2014; Sidibeh et al., 2018), and its methylation could increase the risk of T2D and hyperlipidemia (Ortiz et al., 2018). Here, FKBP5 is linked to hyperlipidemia.